An Official Website of the United States Government
Company Information:
Name:
GLYCOBIA, INC.
Address:
33 Thornwood Drive
ITHACA, NY
ITHACA, NY
Located in HUBZone:
No
Woman-Owned:
No
Minority-Owned:
No
URL:
N/A
Phone:
N/A
Award Totals:
Award List:
Humanizing N-linked glycosylation in Escherichia coli
Award Year / Program / Phase:
2009 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Adam C. Fisher
Award Amount:
$115,988.00
Abstract:
DESCRIPTION (provided by applicant): Protein-based therapeutics currently represent one in every four new drugs approved by the FDA and command a market in excess of 30 billion. The vast majority of therapeutic proteins require additional post-translation
al modifications to attain their full… More
Glycophage arrays for the discovery of biomarkers in disease
Award Year / Program / Phase:
2009 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Adam C. Fisher
Award Amount:
$200,000.00
Abstract:
DESCRIPTION (provided by applicant): Many biological processes throughout the lifespan of a living organism are governed by discrete sugar structures and their interaction with protein and lipid molecules. Such carbohydrates play essential roles in process
es such as cell-cell recognition, adhesion,… More
Glycosylation of full-length antibodies in Escherichia coli
Award Year / Program / Phase:
2009 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Adam C. Fisher
Award Amount:
$82,203.00
Abstract:
DESCRIPTION (provided by applicant): Currently, therapeutic antibodies represent approximately 30% of all biotech revenues (gt 35 billion) and nearly all are produced in mammalian cell culture. Since monoclonal antibodies require glycosylation to provide
full therapeutic benefit, mammalian cell… More
Therapeutic antibody fragments from glycoengineered Escherichia coli
Award Year / Program / Phase:
2010 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Adam C. Fisher
Award Amount:
$391,734.00
Abstract:
DESCRIPTION (provided by applicant): Omalizumab (XolairTM) is a recombinant monoclonal anti-IgE antibody used in the fight against severe allergic asthma that generates 500 million per year. However, 2 out of every 1,000 patients treated with omalizumab s
uffer from anaphylaxis, a severe allergic… More
Conjugation of polysialic acid to biologics in glycoengineered Escherichia coli
Award Year / Program / Phase:
2010 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Adam C. Fisher
Award Amount:
$199,020.00
Abstract:
DESCRIPTION (provided by applicant): Biotherapeutics currently constitute a 70 billion market, but their clinical efficacy is often compromised by limitations arising from proteolytic degradation, uptake by cells of the reticuloendothelial system, renal r
emoval, and immunocomplex formation. This… More
Production of recombinant human glucocerebrosidase in Escherichia coli
Award Year / Program / Phase:
2011 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Adam C. Fisher – 443-677-8849
Award Amount:
$175,860.00
Abstract:
DESCRIPTION (provided by applicant): Gaucher's disease is the most common lysosomal storage disease in humans resulting in the harmful accumulation of fatty glucocerebroside in the spleen, liver, lungs, bone marrow, and brain. Gaucher patients exhibit a hereditary deficiency of… More
Engineering Escherichia coli for glycosylation of complex human proteins
Award Year / Program / Phase:
2011 / SBIR / Phase II
Agency:
HHS
Principal Investigator:
Adam C. Fisher – 443-677-8849
Award Amount:
$1,608,039.00
Abstract:
DESCRIPTION (provided by applicant): Escherichia coli was the host organism for production of the first approved recombinant protein therapeutic in 1982. We now know that most therapeutic proteins require N-linked protein glycosylation to achieve their full clinical efficacy. Since E. coli has not… More